Correction: Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
Jacqui Nimmo(UK Dementia Research Institute), James A. R. Nicoll(University of Southampton), Ajay Verma(Maulana Azad National Institute of Technology), Ronald Melki(Centre National de la Recherche Scientifique), Roxana O. Carare(University of Southampton), Jean‐Cosme Dodart(Merritt College), Chang Yi Wang(Asia University), Jimmy Savistchenko(Centre National de la Recherche Scientifique)
Cited by 2
Related Papers
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
|Nature Neuroscience|2002|858
UB‐311, a novel UBITh <sup>®</sup> amyloid β peptide vaccine for mild Alzheimer's disease
|Alzheimer s & Dementia Translational Research & Clinical Interventions|2017|142
Molecular Interaction between the Chaperone Hsc70 and the N-terminal Flank of Huntingtin Exon 1 Modulates Aggregation
|Journal of Biological Chemistry|2014|85
A Randomized First‐in‐Human Study With UB‐312, a UBITh® α‐Synuclein Peptide Vaccine
|Movement Disorders|2022|51
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
|Alzheimer s Research & Therapy|2020|48